Lithuanian University of Health Sciences

The medical center is at the forefront of cystic fibrosis research, focusing on innovative therapies to improve patient outcomes. The ongoing study of SPL84 aims to enhance the understanding of its safety and tolerability when administered via inhalation, potentially offering new hope for those affected by this challenging condition.

• Inhalation therapies
• Safety and tolerability assessments
• Pharmacokinetics studies

Through rigorous clinical trials, the center is dedicated to identifying the maximum tolerated dose (MTD) of SPL84, paving the way for future therapeutic advancements.

Specializing in nephrology, the center is conducting pivotal research on C3 Glomerulopathy and Idiopathic Immune Complex-Mediated Glomerulonephritis. The study of OMS906 is designed to evaluate its safety and efficacy, providing critical insights into treatment options for these complex kidney disorders.

• Immune-mediated kidney diseases
• Safety and efficacy of novel treatments
• Repeat-dose administration studies

By exploring the effects of OMS906, the center aims to contribute significantly to the development of targeted therapies, improving the quality of life for patients with these conditions.